Animal study · mice

Retatrutide: 14-fold smaller pancreatic tumors in mice

Checked against the paper Animal studyPublished by PepVault

The takeaway

Early animal work links retatrutide-driven weight loss to slower pancreatic and lung tumor growth, but it says nothing yet about cancer in people.

Kind
Animal study
Studied in
Mice
Published
2025
Journal
NPJ Metab Health Dis

What they tested

The team tested whether weight loss from retatrutide changes how obesity-associated cancers take hold and grow in preclinical models.

How the study was done

A preclinical study in a mouse pancreatic cancer model and a lung cancer model, with retatrutide causing significant weight loss. Retatrutide was compared with controls and, in the pancreatic model, with semaglutide, a single agonist.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In mice with pancreatic cancer, retatrutide led to fewer tumors taking hold (engraftment), later tumor onset and slower growth. Tumor volume fell 14-fold, compared with a 4-fold drop in semaglutide-treated mice, and the benefit held even after retatrutide was stopped and weight came back. In the lung cancer model, tumor engraftment was 50% lower, onset came significantly later, and tumor volume was 17-fold smaller than in controls. The animals also showed immune changes, including higher IL-6 in the blood, more antigen-presenting cells (immune cells that flag threats) and fewer immune-suppressing cells.

What it doesn’t show

This was done only in preclinical animal models, so it is not a human result. It did not test whether retatrutide lowers cancer risk or improves cancer outcomes in people.

The paper

Marathe et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. NPJ Metab Health Dis. 2025.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo